"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT03399578","Safety and Immunogenicity of a Candidate MERS-CoV Vaccine (MERS001)",,"Recruiting","No Results Available","MERS (Middle East Respiratory Syndrome)","Biological: ChAdOx1 MERS","Occurrence of solicited and unsolicited local and systemic adverse events|Measures of immunogenicity to the ChAdOx1 MERS vaccine","University of Oxford","All","18 Years to 50 Years   (Adult)","Phase 1","48","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","MERS001","March 14, 2018","July 2021","July 2021","January 16, 2018",,"October 21, 2019","Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03399578"
2,"NCT04119440","Randomized, Double-blind, Placebo-controlled, Phase Ib Study to Assess the Safety and Immunogenicity of MVA-MERS-S_DF-1",,"Not yet recruiting","No Results Available","MERS (Middle East Respiratory Syndrome)","Biological: MVA-MERS-S_DF1 - Low Dose|Biological: MVA-MERS-S_DF1 - High Dose|Other: Placebo","Frequency of adverse events associated with MVA-MERS-S_DF-1.|Frequency and severity of local injection site reactogenicity signs and symptoms|Immunogenicity","Universitätsklinikum Hamburg-Eppendorf|Coalition for Epidemic Preparedness Innovations|IDT Biologika Dessau.Rossau|German Center for Infection Research|CR2O|Clinical Trial Center North (CTC North GmbH & Co. KG)|Erasmus Medical Center","All","18 Years to 55 Years   (Adult)","Phase 1","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CEPI-MVA-MERS-S-Phase1b","May 2020","December 2021","December 2021","October 8, 2019",,"October 8, 2019","CTC North, Hamburg, Germany|Erasmus Medical Centre, Rotterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT04119440"
3,"NCT03615911","Safety, Tolerability and Immunogenicity of Vaccine Candidate MVA-MERS-S",,"Completed","No Results Available","MERS (Middle East Respiratory Syndrome)","Biological: vaccine candidate MVA-MERS-S","Occurrence of solicited local and systemic reactogenicity as defined by the study protocol|Occurrence of unsolicited adverse events|Change from baseline of safety laboratory measures as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4|Occurrence of serious adverse events|Measures of immunogenicity to the MVA-MERS-S vaccine","Marylyn Addo|Philipps University Marburg Medical Center|Ludwig-Maximilians - University of Munich|Charite University, Berlin, Germany|Bernhard Nocht Institute for Tropical Medicine|University of Cologne|Universitätsklinikum Hamburg-Eppendorf","All","18 Years to 55 Years   (Adult)","Phase 1","26","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","UKE-DZIF1-MVA-MERS-S","November 28, 2017","April 15, 2019","May 10, 2019","August 6, 2018",,"October 2, 2019","CTC North GmbH & Co. KG at the University Medical Center Hamburg-Eppendorf, Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT03615911"
4,"NCT04170829","A Clinical Trial to Determine the Safety and Immunogenicity of Healthy Candidate MERS-CoV Vaccine (MERS002)",,"Recruiting","No Results Available","Middle East Respiratory Syndrome Coronavirus","Biological: ChAdOx1 MERS","Occurrence of solicited and unsolicited local and systemic adverse events|Measures of immunogenicity to the ChAdOx1 MERS vaccine","King Abdullah International Medical Research Center|University of Oxford","All","18 Years to 50 Years   (Adult)","Phase 1","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CT18/004/R|MERS002","December 17, 2019","September 1, 2020","January 1, 2021","November 20, 2019",,"February 20, 2020","King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Saudi Arabia",,"https://ClinicalTrials.gov/show/NCT04170829"
5,"NCT02845843","MERS-CoV Infection tReated With A Combination of Lopinavir /Ritonavir and Interferon Beta-1b","MIRACLE","Completed","No Results Available","Middle East Respiratory Syndrome Coronavirus (MERS-CoV)","Drug: Combination of Lopinavir /Ritonavir and Interferon beta-1b|Drug: Placebo","90-day mortality|Organ support-free days (e.g., supplemental O2, ventilator, extracorporeal membrane oxygenation (ECMO), renal replacement and vasopressors)|RT-PCR cycle threshold value in the lower respiratory samples|Sequential organ failure assessment (SOFA) scores|ICU-free days|Length of stay in hospital|Number of Patients with Adverse drug reactions related to the treatment|Karnofsky Performance Scale|ICU mortality|Hospital mortality|28-day mortality","King Abdullah International Medical Research Center","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","95","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","KingAbdullahIMRC","July 2016","May 2020","May 2020","July 27, 2016",,"May 20, 2020","Intensive Care Unit, King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Saudi Arabia|King Abdullah International Medical Research Center, Riyadh, Saudi Arabia",,"https://ClinicalTrials.gov/show/NCT02845843"
6,"NCT04128059","Study of Safety and Immunogenicity of BVRS-GamVac-Combi",,"Recruiting","No Results Available","MERS (Middle East Respiratory Syndrome)|MERS","Drug: BVRS-GamVac-Combi|Other: placebo","Number of Participants With Adverse Events|Number of Participants With Serious Adverse Events|Number of Participants with Solicited Local and Systemic Adverse Events|Antibody levels against the MERS-CoV glycoprotein S measured by an enzyme-linked immunosorbent assay (ELISA)|Assessment of antigen-specific cell-mediated immune response|Neutralizing antibody levels","Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation|Acellena Contract Drug Research and Development","All","18 Years to 55 Years   (Adult)","Phase 1|Phase 2","268","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","02-BVRS-GamVac-Combi-2019","November 6, 2019","December 1, 2020","December 31, 2020","October 16, 2019",,"November 8, 2019","ECO-Safety, Sankt-Peterburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04128059"
7,"NCT04130594","Study of Safety and Immunogenicity of BVRS-GamVac",,"Recruiting","No Results Available","MERS (Middle East Respiratory Syndrome)|MERS","Biological: BVRS-GamVac|Other: placebo","Number of Participants With Adverse Events|Number of Participants With Serious Adverse Events|Number of Participants with Solicited Local and Systemic Adverse Events|Antibody levels against the MERS-CoV glycoprotein S measured by an enzyme-linked immunosorbent assay (ELISA)|Assessment of antigen-specific cell-mediated immune response|Neutralizing antibody levels","Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","All","18 Years to 55 Years   (Adult)","Phase 1|Phase 2","162","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","01-BVRS-GamVac-2019","November 7, 2019","December 1, 2020","December 31, 2020","October 17, 2019",,"November 8, 2019","Research Institute of Influenza, Sankt-Peterburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04130594"
8,"NCT02627378","Saudi Outcomes of ECMO-treated MERS-CoV Patients",,"Completed","No Results Available","MERS-CoV Infection|Refractory Hypoxemia","Other: Extracorporeal Membrane Oxygenation|Other: Non Extracorporeal Membrane Oxygenation","Mortality rate|Use of antiviral medications|Use of steroid medications|Use of interferons|Use of immunoglobulin|Use of vasopressor medications|Use of inotropic medications|Need for renal replacement therapy|Changes in blood cell count|Changes in renal function tests|Changes in arterial blood gases levels|Ratio of arterial oxygen tension (PaO2) to the fraction of inspired oxygen (FiO2) (PaO2/FiO2 ratio)|Use of alveolar recruitment technique|Use of prone ventilation|Use of neuromuscular blockades|Bacterial co-infection|Hospital length of stay|ICU length of stay|Extracorporeal membrane oxygenation support gas flow (liter/min)|Extracorporeal membrane oxygenation support blood flow (liter/min/m2)|Duration of Extracorporeal membrane oxygenation circulatory support","Dammam University|Ministry of Health, Saudi Arabia|King Abdulaziz University","All","18 Years and older   (Adult, Older Adult)","Phase 1","35","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","A-00190","September 2012","June 2015","October 2015","December 10, 2015",,"December 10, 2015","Dammam University KFHU, Al-Khobar, EP, Saudi Arabia",,"https://ClinicalTrials.gov/show/NCT02627378"
9,"NCT02497885","Seroprevalence of MERS-CoV IgG in Healthcare Workers",,"Completed","No Results Available","Coronavirus Infections",,"IgG(+)","Ewha Womans University Mokdong Hospital","All","18 Years and older   (Adult, Older Adult)",,"737","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","KMSG_HCW_IgG","August 2015","October 2015","October 2015","July 15, 2015",,"October 30, 2015","Ewha womans university mokdong hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02497885"
10,"NCT02605109","Analysis of Human to Human Transmission of Middle East Respiratory Syndrom Coronavirus (MER-CoV)","MKU","Completed","No Results Available","Viral Infection","Other: Risk of MERS infection","Numbers of infected patient","Konkuk University Medical Center","All","Child, Adult, Older Adult",,"200","Other","Observational","Observational Model: Case Control|Time Perspective: Retrospective","MERSKORKUH","June 2015","November 2015","November 2015","November 16, 2015",,"September 1, 2016",,,"https://ClinicalTrials.gov/show/NCT02605109"
11,"NCT04322630","Mer-TK in Human Cardiac Cells",,"Active, not recruiting","No Results Available","Myocardial Inflammation|Myocardial Infarction","Other: Change in Soluble MER Concentration","Change in Soluble MER Concentration|Utility of soluble MER as a biomarker of inflammation and injury","Ann & Robert H Lurie Children's Hospital of Chicago","All","up to 19 Years   (Child, Adult)",,"100","Other","Observational","Observational Model: Other|Time Perspective: Other","2019-2445","May 10, 2019","December 31, 2020","December 31, 2020","March 26, 2020",,"March 27, 2020","Ann & Robert H Lurie Children's Hopsital, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04322630"
12,"NCT02190799","Anti-MERS-CoV Convalescent Plasma Therapy",,"Withdrawn","No Results Available","Respiratory Distress Syndrome (& [Hyaline Membrane Disease])","Biological: Convalescent plasma","Hospital mortality|ICU mortality|ICU Length of Stay|Duration of Mechanical Ventilation|Viral load in tracheal aspirate|Inflammatory markers,|Anti-MERS-CoV antibodies","King Abdullah International Medical Research Center","All","14 Years and older   (Child, Adult, Older Adult)","Phase 2","0","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RC13-244","May 2014","May 2016","November 2016","July 15, 2014",,"November 21, 2018","Intensive Care Unit, King Abdulaziz Medical City, Riyadh,, Saudi Arabia",,"https://ClinicalTrials.gov/show/NCT02190799"
13,"NCT03301090","A Safety, Tolerability, Pharmacokinetics and Immunogenicity Trial of Co-administered MERS-CoV Antibodies REGN3048 and REGN3051",,"Completed","No Results Available","Corona Virus Infection","Other: Placebo|Biological: REGN3048|Biological: REGN3051","Changes from baseline in abbreviated physical examination|Changes from baseline in clinical safety laboratory values|Changes from baseline in Electrocardiogram (ECG) parameters|Changes from baseline in symptom-directed physical examination|Changes from baseline in vital signs|The incidence of Adverse Events|The incidence of treatment-emergent Serious Adverse Events|The severity of Adverse Events assessed by toxicity grading criteria|The severity of treatment-emergent Serious Adverse Events assessed by toxicity grading criteria|The type of treatment-emergent Serious Adverse Events|AUC for each dose of REGN3048 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)|AUC for each dose of REGN3051 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)|AUC(0-infinity) for each dose of REGN3048 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)|AUC(0-infinity) for each dose of REGN3051 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)|CL for each dose of REGN3048 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)|CL for each dose of REGN3051 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)|CMAX for each dose of REGN3048 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)|CMAX for each dose of REGN3051 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)|K(e) for each dose of REGN3048 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)|K(e) for each dose of REGN3051 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)|t(1/2) for each dose of REGN3048 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)|t(1/2) for each dose of REGN3051 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)|The change from baseline of antibodies against REGN3048 and REGN3051 (anti-drug antibodies, ADA), as measured in serum using validated bridging assays|TMAX for each dose of REGN3048 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)|TMAX for each dose of REGN3051 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)|V(ss) for each dose of REGN3048 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)|V(ss) for each dose of REGN3051 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 45 Years   (Adult)","Phase 1","48","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","15-0109|HHSN272201500005I","February 12, 2018","January 19, 2019","January 19, 2019","October 4, 2017",,"February 1, 2019","WCCT Global Cypress Clinical Pharmacology Unit, Cypress, California, United States",,"https://ClinicalTrials.gov/show/NCT03301090"
14,"NCT03624062","MER3101: MAS-1 Adjuvanted Antigen-specific Immunotherapeutic for Prevention and Treatment of Type 1 Diabetes","MER3101","Recruiting","No Results Available","Type 1 Diabetes Mellitus","Drug: MAS-1 adjuvanted Insulin B-chain","Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Immunologic Analysis|Mean C-peptide AUC value|HbA1c value|Insulin Use","University of Colorado, Denver|The Leona M. and Harry B. Helmsley Charitable Trust|Nova Immunotherapeutics Limited","All","18 Years to 45 Years   (Adult)","Phase 1","28","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","15-1352","April 2020","April 4, 2022","April 4, 2022","August 9, 2018",,"March 16, 2020","University of Colorado, Denver, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT03624062"
15,"NCT03133429","Clinical Study to Evaluate the Safety and Effectiveness of MER® Stents in Carotid Revascularisation.","MER","Completed","No Results Available","Carotid Artery Stenosis","Device: MER","Stroke within 30 days after the procedure|MAE|Target vessel revascularization within 365 days|Procedure success|SADE","Balton Sp.zo.o.|KCRI","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MER","October 2016","June 22, 2017","June 25, 2019","April 28, 2017",,"November 19, 2019","Małopolskie Centrum Sercowo-Naczyniowe PAKS American Heart of Poland S.A., Oddział Chirurgii naczyniowej, Chrzanow, Poland|Górnośląskie Centrum Medyczne im. prof. Leszka Gieca Uniwersytetu Medycznego w Katowicach, Oddział Chirurgii Ogólnej, Naczyń, Angiologii i Flebologii, Katowice, Poland|Oddział Kliniczny Chorób Serca i Naczyń Krakowski Szpital Specjalistyczny im. Jana Pawła II, Krakow, Poland|Centrum Interwencyjnego Leczenia Udaru i Chorób Naczyniowych Mózgu Instytut Psychiatrii i Neurologii, Warszawa, Poland",,"https://ClinicalTrials.gov/show/NCT03133429"
16,"NCT03547245","A Phase I Trial to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer Vaccine, Adjuvanted",,"Active, not recruiting","No Results Available","HIV/AIDS","Biological: eOD-GT8 60mer + AS01B/ DPBS sucrose/IM|Biological: DPBS Sucrose","Safety and Tolerability: frequency of local and systemic reactogenicity events|Safety and Tolerability: proportion of volunteers with moderate or greater unsolicited adverse events|Safety and Tolerability: proportion of volunteers in each group with potential immune-mediated diseases (pIMDs)|Immunogenicity: Frequency of responses|Immunogenicity: Magnitude of responses","International AIDS Vaccine Initiative","All","18 Years to 50 Years   (Adult)","Phase 1","48","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention","G001","June 15, 2018","January 17, 2020","December 31, 2020","June 6, 2018",,"February 5, 2020","George Washington University, Washington, District of Columbia, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03547245"
17,"NCT02500680","The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101)","MER4101","Active, not recruiting","No Results Available","Influenza, Human","Biological: MER4101|Biological: Inactivated Influenza Vaccine","Number of Participants with solicited local and systemic AEs|Number of Participants with Late-Onset Local and Systemic AEs|Number of Participants with laboratory abnormalities|Occurrence of vaccine-related SAEs|Geometric mean titer (GMT) of hemagglutination inhibition assay (HAI) antibodies|Seroconversion rate of HAI antibody titer|Geometric mean fold increase (GMFI) of HAI antibodies (post-vaccination titer relative to pre-vaccination titer)|Occurrence of unsolicited AEs related to vaccine|Occurrence of adverse events of special interest (AESI)|Comparison of rates of unsolicited AEs related to vaccine at intervals following vaccination|Seroprotection rate of HAI antibody titers (proportion of participants with ≥40 reciprocal antibody titer)","Nova Immunotherapeutics Limited|Mercia Pharma Inc.|Nova Laboratories Limited|The Emmes Company, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 1","102","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","MPE002","July 2015","December 2020","December 2020","July 16, 2015",,"September 6, 2019","Saint Louis University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT02500680"
18,"NCT03329092","A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.","REVISIT","Suspended","No Results Available","Complicated Intra-abdominal Infection|Hosptial Acquired Pneumonia|Ventilator Associated Pneumonia","Drug: ATM-AVI|Drug: MTZ|Drug: MER|Drug: COL","Proportion of subjects with clinical cure in the ITT and CE analysis sets|Proportion of subjects with clinical cure in the m-ITT and ME analysis sets|Proportion of subjects with clinical cure by infection type in the ITT and CE analysis sets.|Proportion of subjects with clinical cure for subjects with MBL positive pathogens in the micro ITT and ME analysis sets.|Proportion of subjects with a favorable per subject microbiological response in the micro ITT and ME analysis sets.|Proportion of subjects who died|PK of ATM|PK/PD relationship between exposure and clinical response for ATM AVI±MTZ in the popPK analysis set|PK of AVI|PK/PD relationship between exposure and clinical response for ATM/AVI +/- MTZ in the popPK analysis set|PK/PD relationship between exposure and microbiological response for ATM/AVI+/-MTZ in the popPK analysis set|Description of safety in terms of adverse events","Pfizer|Innovative Medicines Initiative (IMI) COMBACTE-CARE (EU)|Biomedical Advanced Research and Development Authority","All","18 Years and older   (Adult, Older Adult)","Phase 3","375","Industry|Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","C3601002|D4910C00004|2017-002742-68","April 5, 2018","November 14, 2021","November 30, 2021","November 1, 2017",,"May 20, 2020","Banner University Medical Center - Tucson, Tucson, Arizona, United States|LA BioMed, Harbor-UCLA Medical Center, Torrance, California, United States|Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States|Harbor-UCLA Medical Center, Torrance, California, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|OU Medical Center Hospital, Oklahoma City, Oklahoma, United States|OU Physicians Building, Oklahoma City, Oklahoma, United States|Presbyterian Professional Building, Oklahoma City, Oklahoma, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Hospital Privado de Comunidad, Mar del Plata, Buenos Aires, Argentina|Sanatorio Britanico, Rosario, Santa FE, Argentina|Sanatorio Servicios Medicos SM, Santo Tome, Santa FE, Argentina|Hospital Nuestra Senora de la Misericordia, Cordoba, Argentina|Hospital San Roque, Córdoba, Argentina|First Multiprofile Hospital for Active Treatment - Sofia EAD, Sofia, Bulgaria|University Hospital Alexandrovska, Clinic of Anesthesiology and Intensive Care, Sofia, Bulgaria|University Hospital Queen Joanna ISUL, Clinic of Surgery, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment - Sofia Military Medical Academy, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment ''Prof.Dr Stoyan Kirkovich''AD, Stara Zagora, Bulgaria|Hospital Clinico Universidad de Chile, Santiago de Chile, Region Metropolitana DE Santiago, Chile|Klinicka bolnica Merkur, Zagreb, GRAD Zagreb, Croatia|Klinicki bolnicki centar Rijeka, Rijeka, Primorsko-goranska Zupanija, Croatia|Klinicki bolnicki centar Split, Split, Splitsko-dalmatinska Zupanija, Croatia|Krajska zdravotni, a.s. - Nemocnice Decin, o.z., Decin II, Czechia|Petz Aladar Megyei Oktato Korhaz, Altalanos Sebeszeti Osztaly, Gyor, Hungary|Zala Megyei Szent Rafael Korhaz, Zalaegerszeg, Hungary|King George Hospital, Visakhapatnam, Andhra Pradesh, India|Artemis Hospital, Gurugram, Haryana, India|Victoria Hospital, Bangalore Medical College and Research Institute, Bangalore, Karnataka, India|M S Ramaiah Medical College and Hospitals, Bangalore, Karnataka, India|Kasturba Medical College and Hospital, Manipal, Karnataka, India|JSS Hospital, Mysuru, Karnataka, India|Government Medical College, Kozhikode, Kozhikode, Kerala, India|Deenanath Mangeshkar Hospital And Research Centre, Pune, Maharashtra, India|S.R. Kalla Memorial Gastro & General Hospital, Jaipur, Rajasthan, India|Apollo Hospitals, Chennai, Tamil NADU, India|Sahyadri Specialty Hospital, Pune, India|Rambam Health Care Campus, Haifa, Israel|Hadassah Medical Organization, Hadassah Medical Center, Ein-Karem, Jerusalem, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|The Chaim Sheba Medical Center, Tel-Hashomer, Israel|Shamir Medical Center, Infectious Diseases Unit, Zerifin, Israel|Azienda Ospedaliero Universitaria di Modena, Modena, Italy|Farmacia Ospedaliera - Direzione Assistenza Farmaceutica, Modena, Italy|SC di Radiologia - Azienda Ospedaliera Universitaria di Modena, Modena, Italy|ASST Monza Ospedale San Gerardo Malattie Infettive, Monza, Italy|Farmacia Ospedaliera ASST Monza Ospedale San Gerardo, Monza, Italy|Radiologia ambulatoriale-Palazzina accoglienza ASST Monza Ospedale San Gerardo, Monza, Italy|AORN Dei Colli - Ospedale Cotugno, Napoli, Italy|Servizio Farmacia, Napoli, Italy|Servizio Radiologia, Napoli, Italy|Azienda Ospedaliero-Universitaria Pisana Ospedale Cisanello, Pisa, Italy|UO Radiognastostica 2 Azienda Ospedaliero-Universitaria Pisana Ospedale Cisanello, Pisa, Italy|UO Farmaceutica Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy|Fondazione Policlinico Agostino Gemelli, Roma, Italy|Radiologia d' Urgenza Fondazione Policlinico Agostino Gemelli, Roma, Italy|Servizio di Farmacia Sperimentale Fondazione Policlinico Agostino Gemelli, Roma, Italy|Gachon University Gil Medical Center - Infectious Disease, Incheon, Incheon Gwang'yeogsiv, Korea, Republic of|Dong-A University Hospital, Busan, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|The Catholic University of Korea, Eunpyeong St. Mary's Hospital, Seoul, Korea, Republic of|Hallym University Kangnam Sacred Heart Hospital, Seoul, Korea, Republic of|Hospital Raja Perempuan Zainab II, Kota Bharu, Kelantan, Malaysia|Hospital Raja Permaisuri Bainun, Ipoh, Perak, Malaysia|Hospital Pulau Pinang, George Town, Pulau Pinang, Malaysia|Hospital Seberang Jaya, Seberang Jaya, Pulau Pinang, Malaysia|UMAE Hospital de Especialidades Centro Medico Nacional Siglo XXI, Delegación Cuauhtémoc, Ciudad DE México, Mexico|Hospital Civil Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico|Hospital Universitario ""Dr. Jose Eleuterio Gonzalez"", Monterrey, Nuevo LEON, Mexico|Hospital General 450, Durango, Mexico|Hospital Maria Auxiliadora/Unidad de Investigacion en Oncologia, San Juan de Miraflores, Lima, Peru|Hospital Nacional Adolfo Guevara Velasco, Cusco, Peru|Clinica Internacional - Unidad de Investigacion de la Clinica Internacional, Lima, Peru|Hospital Nacional Dos de Mayo - Centro de Investigacion Medicina Interna, Lima, Peru|Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru|De La Salle Medical and Health Sciences Institute, City Of Dasmarinas, Cavite, Philippines|Davao Doctors Hospital, Davao City, Philippines|St. Paul's Hospital of Iloilo, Inc., Iloilo City, Philippines|West Visayas State University Medical Center, Iloilo City, Philippines|Philippine General Hospital, Central Intensive Care Unit, Manila, Philippines|Philippine General Hospital, Manila, Philippines|Spitalul Clinic de Boli Infectioase si tropicale ""Dr. Victor Babes"", Bucuresti, Romania|Spitalul Clinic de Boli Infectioase Cluj-Napoca, Cluj-Napoca, Romania|Spitalul Clinic de Boli Infectioase ""Sf. Parascheva"" Iasi, Iasi, Romania|Institutul Regional de Oncologie Iasi, Iasi, Romania|Spitalul Clinic Judetean de Urgenta ""Pius Brinzeu"", Timisoara, Romania|GBUZ ""Regional clinical hospital #3"", Chelyabinsk, Russian Federation|NUZ ""Railway Clinical Hospital at the station Chelyabinsk of JSC ""Russian Railways"", Chelyabinsk, Russian Federation|SBHI of the city of Moscow ""City Clinical Hospital named after S.S.Yudin"", Moscow, Russian Federation|SBHI of the city of Moscow ""N.I.Pirogov City Clinical Hospital #1"", Moscow, Russian Federation|GBUZ of the Novosibirsk Region""City Clinical Hospital #2"", Novosibirsk, Russian Federation|GBUZ of the Novosibirsk region ""City Clinical Hospital #25"", Novosibirsk, Russian Federation|State autonomous institution of healthcare of the Perm Region"" City clinical hospital #4"", Perm, Russian Federation|FGBOU VO ""The First St. Petersburg State Medical University n. a. I.P. Pavlova"", Saint Petersburg, Russian Federation|FGBOU VO ""North-West state medical university n.a. I.I. Mechnikov"", Saint-Petersburg, Russian Federation|FGBOU VO ""The First St. Petersburg state medical university n. a. I.P. Pavlova"", Saint-Petersburg, Russian Federation|Clinical Emergency Hospital, Smolensk, Russian Federation|Smolensk Regional Clinical Hospital, Smolensk, Russian Federation|FSBEI HE ""Smolensk State Medical University"" of the Ministry of Health of the Russian Federation, Smolensk, Russian Federation|FSBEI HE ""Smolensk State Medical University"" of the Ministry of Healthcare of the Russian Federation, Smolensk, Russian Federation|Scientific Research Institute of Antimicrobial Chemotherapy, Smolensk, Russian Federation|Helen Joseph Hospital ICU Research Unit, Auckland Park, Gauteng, South Africa|Tiervlei Trial Centre, Cape Town, Western CAPE, South Africa|Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Mutua de Terrassa, Terrassa, Barcelona, Spain|Complejo Hospitalario San Millan y San Pedro de la Rioja. Hospital de San Pedro, Logrono, LA Rioja, Spain|Parc de Salut Mar- Hospital del Mar, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Regional Universitario de Malaga, Malaga, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Universitari i Politecnic la Fe, Valencia, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|National Taiwan University Hospital Yun-Lin Branch, Douliou, Yunlin, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|Taichung Veterans General Hospital, Taichung City, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|Taipei Municipal Wanfang Hospital, Taipei, Taiwan|Srinagarind Hospital, Division of Infectious Disease and Tropical Medicine, Muang, Khon Kaen, Thailand|Bamrasnaradura Infectious Disease Institute (BIDI), Muang Nonthaburi, Nonthaburi, Thailand|Phramongkutklao Hospital, Pulmonary and Critical Care Division, Bangkok, Thailand|Buddhachinnaraj hospital, Phitsanulok, Thailand|Hacettepe Universitesi Tip Fakultesi, Ankara, Turkey|T.C. Saglik Bakanligi Ankara Sehir Hastanesi, Ankara, Turkey|Marmara Universitesi Pendik Egitim Arastirma Hastanesi, Istanbul, Turkey|Ege University Faculty of Medicine, Izmir, Turkey|Karadeniz Technical University Medical Faculty Farabi Hospital, Trabzon, Turkey|OKU ""Chernivetska oblasna klinichna likarnia"", khirurhichne viddilennia, Chernivtsi, Ukraine|KZ ""Dnipropetrovska oblasna klinichna likarnia im. I.I. Mechnykova"", viddilennia khirurhii №2, Dnipro, Ukraine|Komunalnyi zaklad ""Dnipropetrovska miska bahatoprofilna klinichna likarnia #4"", Dnipro, Ukraine|Oblasna klinichna likarnia, viddilennia anesteziolohii ta intensyvnoi terapii,, Ivano-Frankivsk, Ukraine|Ivano-Frankivska tsentralna miska klin likarnia, viddilennia khirurhii,, Ivano-Frankivsk, Ukraine|DU ""Instytut zahalnoi ta nevidkladnoi khirurhii imeni V.T. Zaitseva Natsionalnoi akademii medychnykh, Kharkiv, Ukraine|Kyivska miska klinichna likarnia No. 3, khirurhichne viddilennia, Kyiv, Ukraine|Kyivska miska klinichna likarnia #4, khirurhichne viddilennia #1, Kyiv, Ukraine|Odeska klinichna likarnia na zaliznychnomu transporti filii ""Tsentr okhorony zdorovia"" aktsionernoho, Odesa, Ukraine|Komunalne pidpryiemstvo ""1-a miska klinichna likarnia Poltavskoi miskoi rady"",, Poltava, Ukraine|Vinnytska oblasna klinichna likarnia im. M.I. Pyrohova, klinichnyi tsentr torakalnoi khirurhii, Vinnytsia, Ukraine|Vinnytska oblasna klinichna likarnia im. M.I. Pyrohova, Vinnytsia, Ukraine|Bach Mai Hospital, Hanoi, Vietnam|National Lung hospital, Hanoi, Vietnam|Viet Duc hospital, Hanoi, Vietnam|Trung Vuong Hospital, Ho Chi Minh City, Vietnam",,"https://ClinicalTrials.gov/show/NCT03329092"
19,"NCT00636740","Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients",,"Completed","No Results Available","Hormone-Refractory Prostate Cancer","Drug: Zoledronic Acid 20mg Tablets|Drug: Zoledronic Acid","Effects on 4 markers of bone metabolism|Brief Pain Inventory","Merrion Pharmaceuticals, LLC","Male","18 Years and older   (Adult, Older Adult)","Phase 2","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MER-101-03","February 2008","February 2009","February 2009","March 14, 2008",,"February 20, 2009","Birmingham Hematology & Oncology Associates, LLC, Birmingham, Alabama, United States|Cancer Care of North Florida, P.A., Lake City, Florida, United States|Lakeland Regional Cancer Center, Lakeland, Florida, United States|Innovative Medical Research of South Florida, Inc., Miami, Florida, United States|Green Clinic, LLC, Ruston, Louisiana, United States|New York Urological Associates, PC, New York, New York, United States|Charleston Hematology Oncology Associates, PA, Charleston, South Carolina, United States|Cancer Outreach Associates, P.C., Abingdon, Virginia, United States|East Tallinn Central Hospital, Tallinn, Estonia|North Estonian Regional Hospital, Tallinn, Estonia|Tartu University Hospital, Tartu, Estonia|O. Hublarovs Private Practice, Daugavpils, Latvia|P. Stradina Clinical University Hospital, Riga, Latvia",,"https://ClinicalTrials.gov/show/NCT00636740"
20,"NCT02788188","Safety, Tolerability, and Pharmacokinetics of SAB-301 in Healthy Adults",,"Completed","Has Results","Middle East Respiratory Syndrome Coronavirus","Biological: SAB-301|Other: Normal (9%) Saline","Number of Participants Having Adverse Events","National Institute of Allergy and Infectious Diseases (NIAID)|Naval Medical Research Center|SAB Biotherapeutics Inc.|National Institutes of Health Clinical Center (CC)","All","18 Years to 60 Years   (Adult)","Phase 1","38","NIH|U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","160119|16-I-0119","May 28, 2016","April 10, 2018","April 30, 2018","June 2, 2016","June 12, 2018","June 12, 2018","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT02788188/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02788188"
21,"NCT01883973","MER Versus MRI Guidance DBS in Parkinson's Disease",,"Unknown status","No Results Available","Idiopathic Parkinson's Disease (PD)",,"percentage improvement in the UPDRS part III motor score","Baylor College of Medicine","All","30 Years to 79 Years   (Adult, Older Adult)",,"20","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","H-27630","May 2011","December 2014",,"June 21, 2013",,"June 21, 2013","Baylor College of Medicine, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01883973"
22,"NCT03666468","The Gaming for Medical Education Research (G4MER) Program","G4MER","Recruiting","No Results Available","Education, Medical","Other: PlayMed|Other: Online Package|Other: Paper Guidelines","Multiple choice quiz score|Asthma observed structured clinical examination (OSCE) score|Seizure observed structured clinical examination (OSCE) scoresimulation lab)|Participant attitudes towards educational intervention|Time to specific actions in OSCE scenarios|Anti-epileptic medication(s) administered at correct time during OSCE scenario","The University of New South Wales","All","20 Years to 99 Years   (Adult, Older Adult)","Not Applicable","264","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HC17160-LNR/17/SCHN/194","July 3, 2017","February 28, 2022","April 30, 2022","September 11, 2018",,"July 31, 2019","Sydney Children's Hospital, Randwick, New South Wales, Australia","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT03666468/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03666468"
23,"NCT01056185","Respiratory Virus Hospitalization Study (FLU 003 Plus)",,"Recruiting","No Results Available","Influenza|Novel Respiratory Virus-1 Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV)|Novel Respiratory Virus-2 Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)",,"Death|Recovery from influenza illness (including days lost from normal activities) duration of hospitalization, days in intensive care, days of mechanical ventilation, days of dialysis, pregnancy outcome","University of Minnesota|National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health (NIH)","All","18 Years and older   (Adult, Older Adult)",,"1000","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","0603M83587 FLU 003","August 2009","December 2020","December 2020","January 26, 2010",,"April 2, 2020","UCSD Antiviral Research Center, San Diego, California, United States|George Washington Medical Faculty Associates, Washington, District of Columbia, United States|Washington DC VA Medical Center, Washington, District of Columbia, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Baystate Infectious Diseases Clinical Research, Springfield, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Cooper University Hospital, Camden, New Jersey, United States|New Jersey Medical School Adult Clinical Research Center, Newark, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Cornell CRS, New York, New York, United States|Duke University, Durham, North Carolina, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|University of Tennessee College of Medicine, Chattanooga, Tennessee, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Hospital Nacional Profesor Alejandro Posadas, El Palomar, Buenos Aires, Argentina|Instituto Medico Platense, La Plata, Buenos Aires, Argentina|Hospital Universitario Austral, Pilar, Buenos Aires, Argentina|Hospital Profesor Bernardo Houssay, Vicente Lopez, Buenos Aires, Argentina|Sanatorio Britanico, Rosario, Santa Fe, Argentina|CEMIC, Buenos Aires, Argentina|Hospital General de Agudos JM Ramos Mejia, Buenos Aires, Argentina|Hospital Interzonal General de Agudos Dr. Diego Paroissien, Buenos Aires, Argentina|Hospital Italiano de Buenos Aires, Buenos Aires, Argentina|Hospital Privado Centro Medico de Cordoba, Cordoba, Argentina|Hospital Rawson, Cordoba, Argentina|St. Vincent's Hospital, Darlinghurst, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Centre Hospitalier Universitaire St. Pierre (C.H.U. St. Pierre), Brussels, Belgium|Clinica Alemana, Santiago, Chile|Fundacion Arriaran, Santiago, Chile|Arhus Universitetshospital, Skejby, Aarhus, Denmark|CHIP, Copenhagen, Denmark|Hvidovre University Hospital, Department of Infectious Diseases, Hvidovre, Denmark|Odense University Hospital, Odense, Denmark|Medizinische Universitatsklinik - Bonn, Immunologische Ambulanz CRS, Bonn, Germany|Klinik I fur Innere Medizin der Universitat zu Koln, Studienburo fur Infektiologie u. HIV, Cologne, Germany|Johann Wolfgang Goethe - University Hospital, Infektionsambulanz CRS, Frankfurt, Germany|1st Dept of Critical Care Medicine and Pulmonary Services, Evangelismos Hospital, Athens, Greece|1st Respiratory Medicine Dept, Athens Hosp for Diseases of the Chest ""Sotiria Hospital"", Athens, Greece|Evangelismos General Hospital, Athens, Greece|Hippokration University General Hospital of Athens, Athens, Greece|Hospital Nacional Arzobispo Loayza, Lima, Peru|Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru|Hospital Clinico San Carlos, Madrid, Spain|Hospital La Paz, Madrid, Spain|Hospital Universitario Gregorio Mara�on, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Txagorritxu, Vitoria-Gasteiz, Spain|Chulalongkorn University Hospital, Bangkok, Thailand|Khon Kaen University, Srinagarind Hospital, Khon Kaen, Thailand|Bamrasnaradura Institute, Nonthaburi, Thailand|Heatherwood and Wexham Park Hospitals NHS Foundation Trust, Slough, Berkshire, United Kingdom|Brighton and Sussex University Hospitals NHS Trust, Brighton, East Sussex, United Kingdom|Churchill Hospital, Headington, Oxford, United Kingdom|Sheffield Teaching Hospital NHS Foundation Trust, Sheffield, South Yorkshire, United Kingdom|Bradford Teaching Hospitals NHS Foundation Trust, Bradford, West Yorkshire, United Kingdom|St James's University Hospital, Leeds, West Yorkshire, United Kingdom|Newcastle General Hospital, Newcastle upon Tyne, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01056185"
24,"NCT02320266","Sensory Gating Measured With Microelectrode Recording (MER) During Deep Brain Stimulation (DBS) Surgery",,"Recruiting","No Results Available","Parkinson's Disease|Essential Tremor|Dystonia|Obsessive Compulsive Disorder",,"Changes in EEG (Measurement in response to paired auditory clicks.)|Evaluation of SUA (Single unit analysis of brain response.)|Evaluation of LFP (Local field potential of brain response.)","University of Colorado, Denver","All","18 Years to 80 Years   (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","14-0358","December 2014","December 2020","March 2021","December 19, 2014",,"September 26, 2019","University of Colorado, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT02320266"
25,"NCT03454243","Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors","TITAN","Terminated","No Results Available","Advanced or Metastatic Solid Tumors","Drug: RXDX-106","Dose Limint Toxicities (DLT)|Maximum Tolerated Dose (MTD)|Recommended Phase 2 Dose (RP2D)|Objective Response Rate (ORR)|Duration of Response|Overall Survival (OS)|Progression-Free Survival (PFS)|Maximum observed plasma concentration (Cmax)|Time of maximum observed plasma concentration (Tmax)|AUC throughout dosing interval (AUCτ)","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","1","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RXDX-106-01","February 15, 2018","June 5, 2018","June 5, 2018","March 5, 2018",,"April 25, 2019","START, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03454243"
26,"NCT01139333","Blood and Tumor Tissue Samples From Young Patients With Acute Myeloid Leukemia",,"Completed","No Results Available","Leukemia","Genetic: gene expression analysis|Genetic: western blotting|Other: flow cytometry|Other: laboratory biomarker analysis","Expression of Mer and Axl|Association of abnormal expression of Mer and Axl with induction failure or relapse","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 17 Years   (Child)",,"52","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","AAML10B4|COG-AAML10B4|CDR0000671452|NCI-2011-02222","September 2009","May 2016",,"June 8, 2010",,"May 18, 2016",,,"https://ClinicalTrials.gov/show/NCT01139333"
27,"NCT03960398","Incidence of Iatrogenic Diseases on Hospital's Emergency Consultations","EIU","Completed","No Results Available","Iatrogenic Disease","Drug: Iatrogenic disease impact on emergency consultations","Proportion of patients coming to emergency department because of an adverse drug reaction|Average of patient age among the patients consulting because of an adverse drug reaction|Proportion of male and female patients consulting because of an adverse drug reaction|Number of treatments administered to patients who consult because of an adverse drug reaction|Frequency of the drugs leading to a consultation in emergency department because of an adverse drug reaction","Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer","All","18 Years and older   (Adult, Older Adult)",,"2500","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2019-CHITS-02","June 28, 2019","September 9, 2019","September 9, 2019","May 23, 2019",,"November 29, 2019","Centre Hospitalier Intercommunal de Toulon - La Seyne sur Mer, La Seyne-sur-Mer, Var, France|Centre Hospitalier Intercommunal de Toulon - La Seyne sur Mer, Toulon, Var, France",,"https://ClinicalTrials.gov/show/NCT03960398"
28,"NCT01478867","Detection of Immunotoxic Gluten Peptides in Feces","CELIQK2","Completed","No Results Available","Celiac Disease","Other: Detection of gluten in feces","Monitoring of gluten-free diet compliance in celiac patients","University of Seville|Instituto Hispalense de Pediatría, Seville, Spain","All","1 Year to 12 Years   (Child)",,"53","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CELIQK2","April 2011",,"July 2011","November 23, 2011",,"November 24, 2011","Department of Microbiology and Parasitology, Faculty of Pharmacy, University of Seville, Seville, Spain",,"https://ClinicalTrials.gov/show/NCT01478867"
29,"NCT00603187","ACY-7 Oral Administration of Acyline","ACY-7","Completed","Has Results","Healthy","Drug: Acyline","Testosterone Blood Serum Concentration|FSH Blood Serum Concentration|LH Blood Serum Concentration","University of Washington|Merrion Pharmaceuticals, LLC","Male","18 Years to 50 Years   (Adult)","Phase 1|Phase 2","4","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","32716-W|07-7973-W","January 2008","February 2008","February 2008","January 28, 2008","June 9, 2011","June 9, 2011","University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00603187"
30,"NCT00843882","Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia",,"Active, not recruiting","No Results Available","Anemia|Chronic Myelomonocytic Leukemia|de Novo Myelodysplastic Syndrome|Myelodysplastic Syndrome","Biological: Epoetin Alfa|Other: Laboratory Biomarker Analysis|Drug: Lenalidomide","Major erythroid response (MER)|Time to MER|Duration of MER|Rate of MER|Minor erythroid response rate|Cytogenetic response rate|Bone marrow response (complete response and partial response) rate","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 3","249","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2009-01173|CDR0000634119|ECOG-E2905|09-0095|E2905|U10CA180820|U10CA021115|U24CA196172","January 29, 2009","July 8, 2019",,"February 13, 2009",,"May 14, 2020","University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States|Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States|Alaska Women's Cancer Care, Anchorage, Alaska, United States|Anchorage Oncology Centre, Anchorage, Alaska, United States|Katmai Oncology Group, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|Fairbanks Memorial Hospital, Fairbanks, Alaska, United States|Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Banner University Medical Center - Tucson, Tucson, Arizona, United States|University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States|Kaiser Permanente-Anaheim, Anaheim, California, United States|Kaiser Permanente-Baldwin Park, Baldwin Park, California, United States|Kaiser Permanente-Bellflower, Bellflower, California, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States|Kaiser Permanente-Fontana, Fontana, California, United States|Marin Cancer Care Inc, Greenbrae, California, United States|Kaiser Permanente - Harbor City, Harbor City, California, United States|Kaiser Permanente-Irvine, Irvine, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Kaiser Permanente-Cadillac, Los Angeles, California, United States|Fremont - Rideout Cancer Center, Marysville, California, United States|Stanford Cancer Institute Palo Alto, Palo Alto, California, United States|Kaiser Permanente - Panorama City, Panorama City, California, United States|Kaiser Permanente-Riverside, Riverside, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|Saint Helena Hospital, Saint Helena, California, United States|Kaiser Permanente-San Diego Mission, San Diego, California, United States|Kaiser Permanente-San Diego Zion, San Diego, California, United States|Kaiser Permanente-San Marcos, San Marcos, California, United States|Presbyterian Intercommunity Hospital, Whittier, California, United States|Kaiser Permanente-Woodland Hills, Woodland Hills, California, United States|The Medical Center of Aurora, Aurora, Colorado, United States|Boulder Community Hospital, Boulder, Colorado, United States|Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers-Penrose, Colorado Springs, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States|Rocky Mountain Cancer Centers-Midtown, Denver, Colorado, United States|SCL Health Saint Joseph Hospital, Denver, Colorado, United States|Rocky Mountain Cancer Centers-Rose, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|Western States Cancer Research NCORP, Denver, Colorado, United States|Mercy Medical Center, Durango, Colorado, United States|Mountain Blue Cancer Care Center - Swedish, Englewood, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|Poudre Valley Hospital, Fort Collins, Colorado, United States|Mountain Blue Cancer Care Center, Golden, Colorado, United States|Saint Mary's Hospital and Regional Medical Center, Grand Junction, Colorado, United States|North Colorado Medical Center, Greeley, Colorado, United States|Rocky Mountain Cancer Centers-Greenwood Village, Greenwood Village, Colorado, United States|Rocky Mountain Cancer Centers-Lakewood, Lakewood, Colorado, United States|Saint Anthony Hospital, Lakewood, Colorado, United States|Littleton Adventist Hospital, Littleton, Colorado, United States|Rocky Mountain Cancer Centers-Sky Ridge, Lone Tree, Colorado, United States|Sky Ridge Medical Center, Lone Tree, Colorado, United States|Longmont United Hospital, Longmont, Colorado, United States|McKee Medical Center, Loveland, Colorado, United States|Parker Adventist Hospital, Parker, Colorado, United States|Rocky Mountain Cancer Centers-Parker, Parker, Colorado, United States|Saint Mary Corwin Medical Center, Pueblo, Colorado, United States|North Suburban Medical Center, Thornton, Colorado, United States|SCL Health Lutheran Medical Center, Wheat Ridge, Colorado, United States|University of Connecticut, Farmington, Connecticut, United States|Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States|The Hospital of Central Connecticut, New Britain, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Beebe Medical Center, Lewes, Delaware, United States|Delaware Clinical and Laboratory Physicians PA, Newark, Delaware, United States|Helen F Graham Cancer Center, Newark, Delaware, United States|Medical Oncology Hematology Consultants PA, Newark, Delaware, United States|Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States|Beebe Health Campus, Rehoboth Beach, Delaware, United States|Nanticoke Memorial Hospital, Seaford, Delaware, United States|Holy Cross Hospital, Fort Lauderdale, Florida, United States|Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida, United States|Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Jupiter Medical Center, Jupiter, Florida, United States|Leesburg Regional Medical Center, Leesburg, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|Miami Cancer Institute, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Augusta University Medical Center, Augusta, Georgia, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Fruitland, Fruitland, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Meridian, Meridian, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Nampa, Nampa, Idaho, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Saint Luke's Mountain States Tumor Institute-Twin Falls, Twin Falls, Idaho, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Hematology and Oncology Associates, Chicago, Illinois, United States|Northwestern University, Chicago, Illinois, United States|Presence Resurrection Medical Center, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Weiss Memorial Hospital, Chicago, Illinois, United States|Carle on Vermilion, Danville, Illinois, United States|Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Carle Physician Group-Effingham, Effingham, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Elmhurst Memorial Hospital, Elmhurst, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States|Saint Francis Hospital, Evanston, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|NorthShore University HealthSystem-Glenbrook Hospital, Glenview, Illinois, United States|Hematology Oncology Associates of Illinois-Highland Park, Highland Park, Illinois, United States|NorthShore University HealthSystem-Highland Park Hospital, Highland Park, Illinois, United States|Midwest Center for Hematology Oncology, Joliet, Illinois, United States|Joliet Oncology-Hematology Associates Limited, Joliet, Illinois, United States|Presence Saint Mary's Hospital, Kankakee, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|AMG Libertyville - Oncology, Libertyville, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States|Illinois Cancer Specialists-Niles, Niles, Illinois, United States|Cancer Care Center of O'Fallon, O'Fallon, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|Swedish American Hospital, Rockford, Illinois, United States|SwedishAmerican Regional Cancer Center/ACT, Rockford, Illinois, United States|Hematology Oncology Associates of Illinois - Skokie, Skokie, Illinois, United States|Central Illinois Hematology Oncology Center, Springfield, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|The Carle Foundation Hospital, Urbana, Illinois, United States|Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, United States|Franciscan Saint Francis Health-Beech Grove, Beech Grove, Indiana, United States|Elkhart Clinic, Elkhart, Indiana, United States|Michiana Hematology Oncology PC-Elkhart, Elkhart, Indiana, United States|Elkhart General Hospital, Elkhart, Indiana, United States|Fort Wayne Medical Oncology and Hematology Inc-Parkview, Fort Wayne, Indiana, United States|IU Health Central Indiana Cancer Centers-East, Indianapolis, Indiana, United States|Community Howard Regional Health, Kokomo, Indiana, United States|IU Health La Porte Hospital, La Porte, Indiana, United States|IU Health Arnett Cancer Care, Lafayette, Indiana, United States|Premier Oncology Hematology Associates, Merrillville, Indiana, United States|Memorial Regional Cancer Center Day Road, Mishawaka, Indiana, United States|Michiana Hematology Oncology PC-Mishawaka, Mishawaka, Indiana, United States|Saint Joseph Regional Medical Center-Mishawaka, Mishawaka, Indiana, United States|Michiana Hematology Oncology PC-Plymouth, Plymouth, Indiana, United States|Reid Health, Richmond, Indiana, United States|Memorial Hospital of South Bend, South Bend, Indiana, United States|Michiana Hematology Oncology PC-South Bend, South Bend, Indiana, United States|South Bend Clinic, South Bend, Indiana, United States|Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States|Michiana Hematology Oncology PC-Westville, Westville, Indiana, United States|McFarland Clinic PC - Ames, Ames, Iowa, United States|Mercy Hospital, Cedar Rapids, Iowa, United States|Oncology Associates at Mercy Medical Center, Cedar Rapids, Iowa, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Cancer Center-West Lakes, Clive, Iowa, United States|Mercy Capitol, Des Moines, Iowa, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|Iowa-Wide Oncology Research Coalition NCORP, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Des Moines, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|Iowa Lutheran Hospital, Des Moines, Iowa, United States|Mercy Medical Center - North Iowa, Mason City, Iowa, United States|Ottumwa Regional Health Center, Ottumwa, Iowa, United States|Siouxland Regional Cancer Center, Sioux City, Iowa, United States|Mercy Medical Center-Sioux City, Sioux City, Iowa, United States|Saint Luke's Regional Medical Center, Sioux City, Iowa, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Menorah Medical Center, Overland Park, Kansas, United States|Saint Luke's South Hospital, Overland Park, Kansas, United States|Kansas City NCI Community Oncology Research Program, Prairie Village, Kansas, United States|Advent Health - Shawnee Mission Medical Center, Shawnee Mission, Kansas, United States|Wesley Medical Center, Wichita, Kansas, United States|King's Daughter's Medical Center, Ashland, Kentucky, United States|Flaget Memorial Hospital, Bardstown, Kentucky, United States|Jewish Hospital, Louisville, Kentucky, United States|Jewish Hospital Medical Center Northeast, Louisville, Kentucky, United States|University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States|Saint Agnes Hospital, Baltimore, Maryland, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|Union Hospital of Cecil County, Elkton, Maryland, United States|Frederick Memorial Hospital, Frederick, Maryland, United States|Steward Saint Elizabeth's Medical Center, Brighton, Massachusetts, United States|Lahey Hospital and Medical Center, Burlington, Massachusetts, United States|Holy Family Hospital, Methuen, Massachusetts, United States|UMass Memorial Medical Center - University Campus, Worcester, Massachusetts, United States|Bixby Medical Center, Adrian, Michigan, United States|Hickman Cancer Center, Adrian, Michigan, United States|Michigan Cancer Research Consortium NCORP, Ann Arbor, Michigan, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Beaumont Hospital - Dearborn, Dearborn, Michigan, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Ascension Saint John Hospital, Detroit, Michigan, United States|Green Bay Oncology - Escanaba, Escanaba, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Genesys Regional Medical Center-West Flint Campus, Flint, Michigan, United States|Green Bay Oncology - Iron Mountain, Iron Mountain, Michigan, United States|Allegiance Health, Jackson, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|UP Health System Marquette, Marquette, Michigan, United States|Mercy Memorial Hospital, Monroe, Michigan, United States|Toledo Clinic Cancer Centers-Monroe, Monroe, Michigan, United States|Lakeland Hospital Niles, Niles, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Lake Huron Medical Center, Port Huron, Michigan, United States|Ascension Saint Mary's Hospital, Saginaw, Michigan, United States|Lakeland Medical Center Saint Joseph, Saint Joseph, Michigan, United States|Marie Yeager Cancer Center, Saint Joseph, Michigan, United States|Ascension Providence Hospitals - Southfield, Southfield, Michigan, United States|William Beaumont Hospital - Troy, Troy, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Medini, Eitan MD (UIA Investigator), Alexandria, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Essentia Health Cancer Center, Duluth, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Lake Region Healthcare Corporation-Cancer Care, Fergus Falls, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Hutchinson Area Health Care, Hutchinson, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Minneapolis VA Medical Center, Minneapolis, Minnesota, United States|Health Partners Inc, Minneapolis, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Coborn Cancer Center at Saint Cloud Hospital, Saint Cloud, Minnesota, United States|Saint Cloud Hospital, Saint Cloud, Minnesota, United States|Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|Keesler Medical Center, Keesler Air Force Base, Mississippi, United States|Singing River Hospital, Pascagoula, Mississippi, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|University of Missouri - Ellis Fischel, Columbia, Missouri, United States|Capital Region Southwest Campus, Jefferson City, Missouri, United States|Truman Medical Centers, Kansas City, Missouri, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Saint Joseph Health Center, Kansas City, Missouri, United States|North Kansas City Hospital, Kansas City, Missouri, United States|Heartland Hematology and Oncology Associates Incorporated, Kansas City, Missouri, United States|Kansas City Veterans Affairs Medical Center, Kansas City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Saint Luke's East - Lee's Summit, Lee's Summit, Missouri, United States|Liberty Radiation Oncology Center, Liberty, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Saint Joseph Oncology Inc, Saint Joseph, Missouri, United States|Mercy Hospital South, Saint Louis, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Center for Cancer Care and Research, Saint Louis, Missouri, United States|Comprehensive Cancer Care PC, Saint Louis, Missouri, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Northern Rockies Radiation Oncology Center, Billings, Montana, United States|Saint Vincent Healthcare, Billings, Montana, United States|Montana Cancer Consortium NCORP, Billings, Montana, United States|Saint Vincent Frontier Cancer Center, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Saint James Community Hospital and Cancer Treatment Center, Butte, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Berdeaux, Donald MD (UIA Investigator), Great Falls, Montana, United States|Great Falls Clinic, Great Falls, Montana, United States|Northern Montana Hospital, Havre, Montana, United States|Saint Peter's Community Hospital, Helena, Montana, United States|Glacier Oncology PLLC, Kalispell, Montana, United States|Kalispell Medical Oncology, Kalispell, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Montana Cancer Specialists, Missoula, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|Guardian Oncology and Center for Wellness, Missoula, Montana, United States|CHI Health Saint Francis, Grand Island, Nebraska, United States|CHI Health Good Samaritan, Kearney, Nebraska, United States|Nebraska Cancer Research Center, Lincoln, Nebraska, United States|Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|Alegent Health Immanuel Medical Center, Omaha, Nebraska, United States|Alegent Health Bergan Mercy Medical Center, Omaha, Nebraska, United States|Creighton University Medical Center, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|Nevada Cancer Research Foundation CCOP, Las Vegas, Nevada, United States|Summerlin Hospital Medical Center, Las Vegas, Nevada, United States|OptumCare Cancer Care at Fort Apache, Las Vegas, Nevada, United States|Cheshire Medical Center-Dartmouth-Hitchcock Keene, Keene, New Hampshire, United States|Cooper Hospital University Medical Center, Camden, New Jersey, United States|Veterans Adminstration New Jersey Health Care System, East Orange, New Jersey, United States|Virtua Memorial, Mount Holly, New Jersey, United States|Jersey Shore Medical Center, Neptune, New Jersey, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|Riverview Medical Center/Booker Cancer Center, Red Bank, New Jersey, United States|Community Medical Center, Toms River, New Jersey, United States|Inspira Medical Center Vineland, Vineland, New Jersey, United States|Virtua Voorhees, Voorhees, New Jersey, United States|Inspira Medical Center Woodbury, Woodbury, New Jersey, United States|Montefiore Medical Center-Weiler Hospital, Bronx, New York, United States|Montefiore Medical Center - Moses Campus, Bronx, New York, United States|Hematology Oncology Associates of Central New York-East Syracuse, East Syracuse, New York, United States|Glens Falls Hospital, Glens Falls, New York, United States|Orange Regional Medical Center, Middletown, New York, United States|NYU Winthrop Hospital, Mineola, New York, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Highland Hospital, Rochester, New York, United States|University of Rochester, Rochester, New York, United States|State University of New York Upstate Medical University, Syracuse, New York, United States|Mission Hospital, Asheville, North Carolina, United States|Southeastern Medical Oncology Center-Clinton, Clinton, North Carolina, United States|Southeastern Medical Oncology Center-Goldsboro, Goldsboro, North Carolina, United States|Wayne Memorial Hospital, Goldsboro, North Carolina, United States|Southeastern Medical Oncology Center-Jacksonville, Jacksonville, North Carolina, United States|Rex Cancer Center, Raleigh, North Carolina, United States|Rex Cancer Center of Wakefield, Raleigh, North Carolina, United States|Iredell Memorial Hospital, Statesville, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Mid Dakota Clinic, Bismarck, North Dakota, United States|Saint Alexius Medical Center, Bismarck, North Dakota, United States|Sanford Bismarck Medical Center, Bismarck, North Dakota, United States|Toledo Clinic Cancer Centers-Bowling Green, Bowling Green, Ohio, United States|Mercy Medical Center, Canton, Ohio, United States|Aultman Health Foundation, Canton, Ohio, United States|Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Westside, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Anderson, Cincinnati, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|North Coast Cancer Care-Clyde, Clyde, Ohio, United States|Grandview Hospital, Dayton, Ohio, United States|Good Samaritan Hospital - Dayton, Dayton, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Miami Valley Hospital North, Dayton, Ohio, United States|Dayton NCI Community Oncology Research Program, Dayton, Ohio, United States|Hematology Oncology Center Incorporated, Elyria, Ohio, United States|Mercy Cancer Center-Elyria, Elyria, Ohio, United States|Blanchard Valley Hospital, Findlay, Ohio, United States|Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Saint Rita's Medical Center, Lima, Ohio, United States|Lima Memorial Hospital, Lima, Ohio, United States|Saint Luke's Hospital, Maumee, Ohio, United States|Toledo Clinic Cancer Centers-Maumee, Maumee, Ohio, United States|Toledo Radiation Oncology at Northwest Ohio Onocolgy Center, Maumee, Ohio, United States|Fisher-Titus Medical Center, Norwalk, Ohio, United States|Saint Charles Hospital, Oregon, Ohio, United States|Toledo Clinic Cancer Centers-Oregon, Oregon, Ohio, United States|North Coast Cancer Care, Sandusky, Ohio, United States|ProMedica Flower Hospital, Sylvania, Ohio, United States|Mercy Hospital of Tiffin, Tiffin, Ohio, United States|ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo, Ohio, United States|Saint Vincent Mercy Medical Center, Toledo, Ohio, United States|University of Toledo, Toledo, Ohio, United States|Toledo Community Hospital Oncology Program CCOP, Toledo, Ohio, United States|Mercy Saint Anne Hospital, Toledo, Ohio, United States|Toledo Clinic Cancer Centers-Toledo, Toledo, Ohio, United States|Upper Valley Medical Center, Troy, Ohio, United States|Fulton County Health Center, Wauseon, Ohio, United States|Clinton Memorial Hospital, Wilmington, Ohio, United States|Greene Memorial Hospital, Xenia, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Bay Area Hospital, Coos Bay, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Providence Willamette Falls Medical Center, Oregon City, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|Bryn Mawr Hospital, Bryn Mawr, Pennsylvania, United States|Butler Memorial Hospital, Butler, Pennsylvania, United States|Carlisle Regional Cancer Center, Carlisle, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Ephrata Cancer Center, Ephrata, Pennsylvania, United States|Ephrata Community Hospital, Ephrata, Pennsylvania, United States|Adams Cancer Center, Gettysburg, Pennsylvania, United States|Cherry Tree Cancer Center, Hanover, Pennsylvania, United States|Geisinger Medical Center-Cancer Center Hazleton, Hazleton, Pennsylvania, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|Lewistown Hospital, Lewistown, Pennsylvania, United States|Riddle Memorial Hospital, Media, Pennsylvania, United States|Paoli Memorial Hospital, Paoli, Pennsylvania, United States|University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States|Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|Phoenixville Hospital, Phoenixville, Pennsylvania, United States|Pottstown Hospital, Pottstown, Pennsylvania, United States|Penn State Health Saint Joseph Medical Center, Reading, Pennsylvania, United States|Guthrie Medical Group PC-Robert Packer Hospital, Sayre, Pennsylvania, United States|Geisinger Medical Group, State College, Pennsylvania, United States|Mount Nittany Medical Center, State College, Pennsylvania, United States|Chester County Hospital, West Chester, Pennsylvania, United States|Reading Hospital, West Reading, Pennsylvania, United States|Geisinger Wyoming Valley/Henry Cancer Center, Wilkes-Barre, Pennsylvania, United States|UPMC Susquehanna, Williamsport, Pennsylvania, United States|Lankenau Medical Center, Wynnewood, Pennsylvania, United States|WellSpan Health-York Hospital, York, Pennsylvania, United States|Prisma Health Cancer Institute - Easley, Easley, South Carolina, United States|Greenville Health System Cancer Institute-Andrews, Greenville, South Carolina, United States|Saint Francis Hospital, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Butternut, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Faris, Greenville, South Carolina, United States|Prisma Health Greenville Memorial Hospital, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Eastside, Greenville, South Carolina, United States|Self Regional Healthcare, Greenwood, South Carolina, United States|Prisma Health Cancer Institute - Greer, Greer, South Carolina, United States|Prisma Health Cancer Institute - Seneca, Seneca, South Carolina, United States|Prisma Health Cancer Institute - Spartanburg, Spartanburg, South Carolina, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Avera McKennan Hospital and University Health Center, Sioux Falls, South Dakota, United States|Thompson Cancer Survival Center, Knoxville, Tennessee, United States|The Don and Sybil Harrington Cancer Center, Amarillo, Texas, United States|University of Virginia Cancer Center, Charlottesville, Virginia, United States|Danville Regional Medical Center, Danville, Virginia, United States|Fredericksburg Oncology Inc, Fredericksburg, Virginia, United States|Sovah Health Martinsville, Martinsville, Virginia, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, United States|Harrison HealthPartners Hematology and Oncology-Bremerton, Bremerton, Washington, United States|Swedish Cancer Institute-Edmonds, Edmonds, Washington, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|EvergreenHealth Medical Center, Kirkland, Washington, United States|PeaceHealth Saint John Medical Center, Longview, Washington, United States|Skagit Valley Hospital, Mount Vernon, Washington, United States|Harrison HealthPartners Hematology and Oncology-Poulsbo, Poulsbo, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Minor and James Medical PLLC, Seattle, Washington, United States|Pacific Medical Center-First Hill, Seattle, Washington, United States|Swedish Medical Center-Ballard Campus, Seattle, Washington, United States|Kaiser Permanente Washington, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|Cancer Care Northwest - Spokane South, Spokane, Washington, United States|Evergreen Hematology and Oncology PS, Spokane, Washington, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States|Wenatchee Valley Hospital and Clinics, Wenatchee, Washington, United States|West Virginia University Charleston Division, Charleston, West Virginia, United States|West Virginia University Healthcare, Morgantown, West Virginia, United States|Camden Clark Medical Center, Parkersburg, West Virginia, United States|Princeton Community Hospital, Princeton, West Virginia, United States|ThedaCare Regional Cancer Center, Appleton, Wisconsin, United States|Aurora Cancer Care-Southern Lakes VLCC, Burlington, Wisconsin, United States|Marshfield Clinic-Chippewa Center, Chippewa Falls, Wisconsin, United States|Marshfield Clinic Cancer Center at Sacred Heart, Eau Claire, Wisconsin, United States|Aurora Health Care Germantown Health Center, Germantown, Wisconsin, United States|Aurora Cancer Care-Grafton, Grafton, Wisconsin, United States|Green Bay Oncology at Saint Vincent Hospital, Green Bay, Wisconsin, United States|Saint Vincent Hospital Cancer Center Green Bay, Green Bay, Wisconsin, United States|Green Bay Oncology Limited at Saint Mary's Hospital, Green Bay, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay, Wisconsin, United States|Aurora BayCare Medical Center, Green Bay, Wisconsin, United States|Mercyhealth Hospital and Cancer Center - Janesville, Janesville, Wisconsin, United States|UW Cancer Center Johnson Creek, Johnson Creek, Wisconsin, United States|Aurora Cancer Care-Kenosha South, Kenosha, Wisconsin, United States|Gundersen Lutheran Medical Center, La Crosse, Wisconsin, United States|Dean Hematology and Oncology Clinic, Madison, Wisconsin, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Holy Family Memorial Hospital, Manitowoc, Wisconsin, United States|Aurora Bay Area Medical Group-Marinette, Marinette, Wisconsin, United States|Bay Area Medical Center, Marinette, Wisconsin, United States|Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, United States|Marshfield Medical Center, Marshfield, Wisconsin, United States|Aurora Cancer Care-Milwaukee, Milwaukee, Wisconsin, United States|Aurora Saint Luke's Medical Center, Milwaukee, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Aurora Sinai Medical Center, Milwaukee, Wisconsin, United States|Marshfield Clinic-Minocqua Center, Minocqua, Wisconsin, United States|ProHealth D N Greenwald Center, Mukwonago, Wisconsin, United States|Cancer Center of Western Wisconsin, New Richmond, Wisconsin, United States|ProHealth Oconomowoc Memorial Hospital, Oconomowoc, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Oconto Falls, Oconto Falls, Wisconsin, United States|Vince Lombardi Cancer Clinic - Oshkosh, Oshkosh, Wisconsin, United States|Aurora Cancer Care-Racine, Racine, Wisconsin, United States|Ascension Saint Mary's Hospital, Rhinelander, Wisconsin, United States|Marshfield Medical Center-Rice Lake, Rice Lake, Wisconsin, United States|HSHS Saint Nicholas Hospital, Sheboygan, Wisconsin, United States|Vince Lombardi Cancer Clinic-Sheboygan, Sheboygan, Wisconsin, United States|Ascension Saint Michael's Hospital, Stevens Point, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Sturgeon Bay, Sturgeon Bay, Wisconsin, United States|Green Bay Oncology - Sturgeon Bay, Sturgeon Bay, Wisconsin, United States|Aurora Medical Center in Summit, Summit, Wisconsin, United States|Vince Lombardi Cancer Clinic-Two Rivers, Two Rivers, Wisconsin, United States|Aurora Cancer Care-Waukesha, Waukesha, Wisconsin, United States|ProHealth Waukesha Memorial Hospital, Waukesha, Wisconsin, United States|UW Cancer Center at ProHealth Care, Waukesha, Wisconsin, United States|Aspirus Regional Cancer Center, Wausau, Wisconsin, United States|Aurora Cancer Care-Milwaukee West, Wauwatosa, Wisconsin, United States|Aurora West Allis Medical Center, West Allis, Wisconsin, United States|Marshfield Clinic - Weston Center, Weston, Wisconsin, United States|Aspirus UW Cancer Center, Wisconsin Rapids, Wisconsin, United States|Marshfield Clinic - Wisconsin Rapids Center, Wisconsin Rapids, Wisconsin, United States|Rocky Mountain Oncology, Casper, Wyoming, United States|Welch Cancer Center, Sheridan, Wyoming, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT00843882/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT00843882"
31,"NCT04412395","Clinical Assessment of Oral Lactoferrin as a Safe Antiviral and Immunoregulatory in Treating COVID-19 Disease","COVID-19_LF","Not yet recruiting","No Results Available","Corona Virus Infection|Middle East Respiratory Syndrome (MERS)|Acute Respiratory Distress Syndrome|Coronavirus Infection|COVID-19|SARS-CoV 2","Dietary Supplement: Lactoferrin (Apolactoferrin)|Drug: Placebo of excipient(s) will be administered","Survival rate.|Rate of disease remission.|The number of patients with PCR negative results.|Mean change in the disease severity (clinical assessment).|Mean change in blood pressure.|Mean change in heart beats.|Mean change in body temperature.|Mean change in body respiratory rate.|Mean change in oxygen saturation.|Mean change in the ratio in arterial oxygen partial pressure to fractional inspired oxygen (PF ratio).|Mean change in complete blood picture (CBC).|Mean change in C reactive protein (CRP).|Mean change in erythrocyte sedimentation rate (ESR).|Mean change in D-dimer.|Mean change in ferritin.|Mean change in liver Albumin.|Mean change in total and direct Bilirubin.|Mean change in prothrombin time (PT) and partial thromboplastin time (PTT ).|Mean change in aspartate aminotransferase (AST).|Mean change in Alanine Aminotransferase (ALT).|Mean change in Blood Urea Nitrogen (BUN).|Mean change in Serum Creatinine.|Mean change in Serum Creatinine clearance.|Mean change in Glomerular filtration rate (GFR ).|The mean change in serum interleukin-1 (IL-1).|The mean change in serum interleukin-6 (IL-6).|The mean change in serum interleukin-10 (IL-10).|The mean change in serum tumor necrosis factor-alpha (TNF alpha).|Mean changes in immunoglobulin G (IgG).|Mean changes in immunoglobulin M (IgM).|The mean change in PCR viral load.|Mean change in lung CT manifestation.|Nature and severity of Adverse Events.|Time for lung recovery.|The number of missed drug doses among each treatment group.","National Research Center, Egypt|Egyptian Military Medical Services","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","516","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","COVID-19_LF","June 1, 2020","August 31, 2020","September 30, 2020","June 2, 2020",,"June 2, 2020","National Research Center, Egypt (Clinical and Molecular Pharmacology), Cairo, Giza, Egypt|Clinmax CRO (Clinical Research Organization), Cairo, Egypt|Clinical Trial Unit National Research Center, Cairo, Egypt|Egyptian Military Medical Services (Hospitals), Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT04412395"
32,"NCT03721718","Evaluate the Safety, Tolerability and Immunogenicity Study of GLS-5300 in Healthy Volunteers",,"Completed","No Results Available","Healthy","Biological: GLS-5300|Device: Cellectra 2000 Electroporation","Incidence of adverse events|Administration (injection) site reactions|Changes in safety laboratory parameters|Administration (injection) site pain|Cellular Immune Responses|Binding antibody titers|Neutralizing antibodies","GeneOne Life Science, Inc.|Inovio Pharmaceuticals|International Vaccine Institute","All","19 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","60","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","MERS-002","August 28, 2018","May 30, 2019","April 22, 2020","October 26, 2018",,"May 27, 2020","Seoul National University Bundang Hospital, Seongnam, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03721718"
33,"NCT02670187","Phase I, Open Label Dose Ranging Safety Study of GLS-5300 in Healthy Volunteers",,"Completed","No Results Available","Healthy","Biological: GLS-5300","Mean change from baseline in safety laboratory measures|Incidence of solicited adverse events after vaccination|Incidence of unsolicited adverse events after vaccination|Incidence of serious adverse events|Binding antibody response to S protein|Neutralizing antibody response to S protein|T cell response","GeneOne Life Science, Inc.|Inovio Pharmaceuticals|Walter Reed Army Institute of Research (WRAIR)","All","18 Years to 50 Years   (Adult)","Phase 1","75","Industry|U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","WRAIR 2274","February 2016","May 2017","September 2017","February 1, 2016",,"January 9, 2019","Walter Reed Institute of Research, Silver Spring, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02670187"
34,"NCT03522142","A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies",,"Recruiting","No Results Available","Advanced Solid Tumors","Drug: INCB081776|Drug: INCMGA00012","Part 1 and Part 2: Number of treatment-emergent adverse events (TEAEs)|Part 1 and Part 2: Cmax of INCB081776|Part 1 and Part 2: Tmax of INCB081776|Part 1 and Part 2: t½ of INCB081776|Part 1 and Part 2: Pharmacokinetic/ pharmacodynamic correlation|Part 1 and Part 2: Overall response rate|Part 1 and Part 2: Disease control rate|Part 1 and Part 2: Duration of response|Part 1 and Part 2: AUC0-t of INCB081776|Part 1 and Part 2: Cmin of INCB081776|Part 1 and Part 2: AUC0-∞ of INCB081776|Part 1 and Part 2 : CL/F of INCB081776|Part 1 and Part 2 : λz of INCB081776|Part 1 and Part 2 : Vz/F of INCB081776","Incyte Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","180","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","INCB 81776-101","May 24, 2018","August 31, 2020","October 31, 2020","May 11, 2018",,"March 24, 2020","Yale Cancer Center, New Haven, Connecticut, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03522142"
35,"NCT03283150","Deep Brain Stimulation (DBS) Sedation",,"Recruiting","No Results Available","Brain|Sedation","Drug: Remifentanil|Drug: Propofol|Drug: Dexmedetomidine","Sedatives drugs effects|Time|Database","University of Wisconsin, Madison","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 4","180","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016-1420|A530900|SMPH\ANESTHESIOLOGY\ANESTHESIO","December 1, 2017","December 31, 2020","December 31, 2022","September 14, 2017",,"December 19, 2019","University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03283150"
36,"NCT04415359","Evaluation of the Evolution of Pregnancies in the First Trimester Following MAR Management During a COVD-19 Pandemic Period","AMPCOVID-19","Recruiting","No Results Available","Covid-19",,"Evaluation of the evolution of pregnancies in the first trimester following MAR management during a COVD-19 pandemic period","University Hospital, Strasbourg, France","Female","18 Years to 43 Years   (Adult)",,"700","Other","Observational","Observational Model: Case-Only|Time Perspective: Other","7789","May 20, 2020","July 2020","July 2020","June 4, 2020",,"June 4, 2020","Service Clinico biologique d'Assistance Médicale à La Procréation, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT04415359"
37,"NCT04116242","MERTK Signalling in Monocytes/Macrophages in Patients With Liver Disease",,"Recruiting","No Results Available","Liver Disease|Cirrhosis of the Liver|Acute-On-Chronic Liver Failure|Liver Failure","Other: blood sampling for research purpose|Other: clinical data collection|Other: Health-related Questionnaires|Other: Sampling other biological materials (e.g. liver biopsies, liver resections, ascites, urine, gut biopsies)","Change in MERTK signalling cascade on monocytes|Change in MERTK signalling cascade on tissue macrophages|Change in mechanism of MERTK activation in cell culture models using monocytes","University Hospital, Basel, Switzerland|Swiss National Science Foundation","All","18 Years and older   (Adult, Older Adult)",,"240","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","EKSG 15/074; me19Bernsmeier2","August 27, 2015","August 2020","December 2020","October 4, 2019",,"October 4, 2019","University Hospital Basel, Hepatology Department and Laboratory, Basel, Switzerland|Cantonal Hospital St. Gallen, St. Gallen, Switzerland|King's College Hospital, Institute of Liver studies, London, United Kingdom|St. Mary's Hospital, Imperial College London, Section of Hepatology, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04116242"
38,"NCT03176277","A Study of ONO-7475 in Patients With Acute Leukemias",,"Active, not recruiting","No Results Available","Acute Leukemia|Myelodysplastic Syndromes","Drug: ONO-7475","Incidence, nature, and severity of (serious) Adverse Events|Clinically significant ophthalmology examinations|Clinically significant electrocardiogram (ECG)|Determination of Maximum Tolerated Dose (MTD)|Determination of recommended pharmacological dose|Pharmacokinetics (Tmax)|Pharmacokinetics (Cmax)|Pharmacokinetics (AUC)|Pharmacokinetics (T1/2)|Pharmacokinetics (Ctrough)|Pharmacokinetics (Cmax) - Food effect|Pharmacokinetics (Tmax) - - Food effect|Pharmacokinetics (AUC) - Food effect|Pharmacokinetics (T1/2) - Food effect|Pharmacokinetics (Ctrough) - Food effect|Pharmacodynamics of ONO-7475|Overall response rate (ORR)|Duration of response (DOR)|Event-free survival|Complete Response without minimal residual disease (MRD) AML & ALL","Ono Pharmaceutical Co. Ltd","All","18 Years and older   (Adult, Older Adult)","Phase 1","42","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ONO-7475-01","June 26, 2017","September 11, 2020","March 8, 2021","June 5, 2017",,"June 5, 2020","University of Southern California, Los Angeles, California, United States|University of California, Los Angeles, California, United States|University of Kansas Cancer Center, Fairway, Kansas, United States|University of Michigan, Ann Arbor, Michigan, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Weill Medical College of Cornell University, New York, New York, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Medical University of South Carolina - Hollins Cancer Center, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03176277"
39,"NCT01056354","Respiratory Virus Outpatient Study (FLU 002 Plus)",,"Completed","No Results Available","Influenza and Other Novel Respiratory Viruses",,"Death or Hospitalization|Days of work/school lost, duration of symptoms, use of antivirals","University of Minnesota|National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health (NIH)","All","18 Years and older   (Adult, Older Adult)",,"11719","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","0603M83587 FLU 002|HHSN261200800001E ; 29XS214","August 2009","May 12, 2017","May 12, 2017","January 26, 2010",,"August 18, 2017","UCSD Antiviral Research Center, San Diego, California, United States|Denver Public Health, Denver, Colorado, United States|George Washington Medical Faculty Associates, Washington, D.C., District of Columbia, United States|Washington DC VA Medical Center, Washington, D.C., District of Columbia, United States|Infectious Diseases Associates NW FL, PA, Pensacola, Florida, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Henry Ford Health System, Detroit, Michigan, United States|Newland Immunology Center of Excellence (NICE), Southfield, Michigan, United States|New Jersey Medical School Adult Clinical Research Center, Newark, New Jersey, United States|Cornell CRS, New York, New York, United States|Bronx-Lebanon Hospital Center, The Bronx, New York, United States|UNC AIDS Clinical Trials Unit, Chapel Hill, North Carolina, United States|Duke University, Durham, North Carolina, United States|University of Tennessee College of Medicine, Chattanooga, Tennessee, United States|University of North Texas Health Science Center, Fort Worth, Texas, United States|Houston AIDS Research Team, Houston, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Hospital Nacional Profesor Alejandro Posadas, El Palomar, Buenos Aires, Argentina|Hospital Interzonal General de Agudos Dr. Diego Paroissien, La Matanza, Buenos Aires, Argentina|Instituto Medico Platense, La Plata, Buenos Aires, Argentina|Hospital Profesor Bernardo Houssay, Vicente Lopez, Buenos Aires, Argentina|CAICI (Instituto Centralizado de Assistencia e Investigacion Clinica Integral), Rosario, Santa Fe, Argentina|Sanatorio Britanico, Rosario, Santa Fe, Argentina|CEMIC, Buenos Aires, Argentina|FUNCEI, Buenos Aires, Argentina|Hospital General de Agudos JM Ramos Mejia, Buenos Aires, Argentina|Hospital Italiano de Buenos Aires, Buenos Aires, Argentina|Hospital Privado Centro Medico de Cordoba, Cordoba, Argentina|Hospital Rawson, Cordoba, Argentina|Interchange General Practice, Canberra, Australian Capital Territory, Australia|Holdsworth House Medical Practice, Darlinghurst, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Prahran Market Clinic, Melbourne, Victoria, Australia|Northside Clinic, North Fitzroy, Victoria, Australia|Centre Hospitalier Universitaire St. Pierre (C.H.U. St. Pierre), Brussels, Belgium|Practimed Medisch Centrum Tessenderlo, Tessenderlo, Belgium|Clinica Alemana, Santiago, Chile|Fundacion Arriaran, Santiago, Chile|Pontificia Universidad Catolica de Chile, Santiago, Chile|Arhus Universitetshospital, Skejby, Aarhus, Denmark|CHIP, Copenhagen, Denmark|Rigshospitalet, Infektionsmedicinsk ambulatorium 8622, Copenhagen, Denmark|University Clinic of General Practice, Copenhagen, Denmark|West Tallinn Central Hospital Infectious Diseases, Tallinn, Estonia|Medizinische Universitatsklinik - Bonn, Immunologische Ambulanz CRS, Bonn, Germany|Klinik I fur Innere Medizin der Universitat zu Koln, Studienburo fur Infektiologie u. HIV, Cologne, Germany|Johann Wolfgang Goethe - University Hospital, Infektionsambulanz CRS, Frankfurt, Germany|Ifi - Studien und Projekte GmbH, Hamburg, Germany|1st Dept of Critical Care Medicine and Pulmonary Services, Evangelismos Hospital, Athens, Greece|1st Respiratory Medicine Dept, Athens Hosp for Diseases of the Chest ""Sotiria Hospital"", Athens, Greece|Evangelismos General Hospital, Athens, Greece|Hippokration University General Hospital of Athens, Athens, Greece|National Hospital Organization Nagoya Medical Center, Nagoya, Japan|Hospital Nacional Arzobispo Loayza, Lima, Peru|Asociacion Civil IMPACTA Salud y Educacion, Lima, Peru|Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru|Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru|Wojewodzki Szpital Zakazny, Warsaw, Poland|EMC Instytut Medyczny SA, Wroclaw, Poland|Hospital Universitario y Politécnico La Fe, Valencia, Spain|Hospital Txagorritxu, Vitoria-Gasteiz, Spain|Chulalongkorn University Hospital, Bangkok, Thailand|Khon Kaen University, Srinagarind Hospital, Khon Kaen, Thailand|Bamrasnaradura Institute, Nonthaburi, Thailand|Norfolk and Norwich University Hospital, Norwich, Norfolk, United Kingdom|Churchill Hospital, Headington, Oxford, United Kingdom|Bradford Teaching Hospitals NHS Foundation Trust, Bradford, West Yorkshire, United Kingdom|St James's University Hospital, Leeds, West Yorkshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01056354"
